Trade Summary

1 month ago, Kelly Paul Edward, serving as COO at Relmada Therapeutics, Inc. (RLMD), purchased 90,000 shares at $2.20 per share, for a total transaction value of $198,000.00. Following this transaction, Kelly Paul Edward now holds 502,295 shares of RLMD.

This purchase represents a 22.00% increase in Kelly Paul Edward's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, November 5, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, November 6, 2025, 1 day after the trade was made.

Relmada Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.